肺癌是VTE发病率最高的恶性肿瘤之一,VTE的发生是一个重要的医疗问题,具有多种不良后果,为了更有效预测血栓栓塞事件,国内外已经开发了癌症患者的风险评估工具。这些评估工具在肺癌患者VTE中有不同程度的预测价值。KRS被相关指南推荐用于评估癌症门诊患者VTE的风险,且预测价值可观。但在肺癌患者中虽然有较高特异性,却缺乏鉴别能力,对于VTE风险分层能力欠佳。新一代KRS的提出在癌症患者中在一定程度上提高了预测准确性,但在识别VTE高风险肺癌患者方面的表现较差。COMPASS-CAT不仅在实体器官恶性肿瘤验证研究中表现出色,还是肺恶性肿瘤患者VTE发病率的最精确预测因子,适用于肺癌患者VTE风险筛查及监测。ROADMAP-CAT RAM风险因子中含有不易测得的生物标志物,不适合临床应用。本综述总结既往研究,概述了肺癌发生静脉血栓栓塞的多种风险评估工具。效能好的RAM为临床医生识别患者潜在VTE风险的最佳工具,有助于识别符合血栓预防条件的高危患者,做到早预防早治疗。Lung cancer is one of the malignancies with the highest incidence of venous thromboembolism (VTE). The occurrence of VTE is a significant medical issue associated with a variety of adverse consequences. To more effectively predict thromboembolic events, risk assessment tools for cancer patients have been developed both domestically and internationally. These assessment tools have varying degrees of predictive value in VTE in lung cancer patients. KRS is recommended by relevant guidelines to assess the risk of VTE in cancer outpatients and has considerable predictive value. However, although it has high specificity in lung cancer patients, it lacks the ability to distinguish and has a poor ability to stratify the risk of VTE. The proposal of a new generation of KRS has improved the prediction accuracy to a certain extent in cancer patients, but it has performed poorly in identifying
